B7-H3 Oncology Pipeline Poised for Market Expansion Through 2036

The B7-H3 (CD276) protein has emerged as a high-priority target for developers seeking to address difficult-to-treat malignancies, including lung, prostate, breast, and head and neck cancers. Unlike traditional treatments, B7-H3-directed therapies offer a precision approach that minimizes systemic toxicity. Current development efforts are concentrated on a variety of modalities, ranging from antibody-drug conjugates (ADCs) to bispecific antibodies and CAR-T cell therapies.

Major pharmaceutical players, including Daiichi Sankyo, MacroGenics, and BioNTech, are currently advancing candidates through clinical trials. Notably, Daiichi Sankyo’s Ifinatamab deruxtecan has already secured breakthrough therapy designation from the U.S. FDA for extensive-stage small cell lung cancer following positive Phase II data. Similarly, DualityBio and BioNTech are progressing with their candidate, Elfetabart drozuntecan, in pivotal trials for metastatic castration-resistant prostate cancer. According to DelveInsight, while no B7-H3-targeted inhibitor has yet reached commercial approval, the active pipeline suggests that these agents will fundamentally reshape oncology treatment landscapes across the U.S., EU4, the U.K., and Japan over the next decade.